Zacks: Brokerages Anticipate Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) to Post -$0.12 EPS

Brokerages predict that Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) will post earnings of ($0.12) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aerpio Pharmaceuticals’ earnings. Aerpio Pharmaceuticals posted earnings of ($0.22) per share in the same quarter last year, which suggests a positive year over year growth rate of 45.5%. The business is scheduled to report its next quarterly earnings results on Tuesday, August 13th.

On average, analysts expect that Aerpio Pharmaceuticals will report full year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.61) to ($0.56). For the next financial year, analysts expect that the firm will post earnings of ($0.37) per share, with EPS estimates ranging from ($0.42) to ($0.32). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Aerpio Pharmaceuticals.

Aerpio Pharmaceuticals (NYSE:ARPO) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.01).

Separately, HC Wainwright lowered Aerpio Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, March 19th.

Shares of NYSE ARPO traded down $0.01 during mid-day trading on Friday, hitting $0.97. 900 shares of the stock traded hands, compared to its average volume of 403,317. Aerpio Pharmaceuticals has a twelve month low of $0.88 and a twelve month high of $4.95.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy.

Featured Story: Gap Up Stocks

Get a free copy of the Zacks research report on Aerpio Pharmaceuticals (ARPO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with's FREE daily email newsletter.